Denali Therapeutics, Inc. (DNLI)
19.45
+0.78
(+4.18%)
USD |
NASDAQ |
Oct 09, 16:00
19.46
+0.01
(+0.03%)
After-Hours: 20:00
Denali Therapeutics Free Cash Flow : -466.26M for June 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -466.26M |
| March 31, 2026 | -419.23M |
| December 31, 2025 | -422.10M |
| September 30, 2025 | -410.85M |
| June 30, 2025 | -367.95M |
| March 31, 2025 | -384.38M |
| December 31, 2024 | -363.61M |
| September 30, 2024 | -375.69M |
| June 30, 2024 | -402.10M |
| March 31, 2024 | -425.11M |
| December 31, 2023 | -370.93M |
| September 30, 2023 | -347.55M |
| June 30, 2023 | -321.22M |
| March 31, 2023 | -247.99M |
| December 31, 2022 | -262.55M |
| September 30, 2022 | -253.58M |
| Date | Value |
|---|---|
| June 30, 2022 | -233.80M |
| March 31, 2022 | -243.00M |
| December 31, 2021 | -219.89M |
| September 30, 2021 | 361.38M |
| June 30, 2021 | 404.07M |
| March 31, 2021 | 415.39M |
| December 31, 2020 | 413.06M |
| September 30, 2020 | -150.08M |
| June 30, 2020 | -182.74M |
| March 31, 2020 | -192.52M |
| December 31, 2019 | -169.50M |
| September 30, 2019 | -27.33M |
| June 30, 2019 | -29.72M |
| March 31, 2019 | -18.67M |
| December 31, 2018 | 46.72M |
| September 30, 2018 | -64.43M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -75.11M |
| Oncolytics Biotech, Inc. | -26.53M |
| Sangamo Therapeutics, Inc. | -90.46M |
| Sarepta Therapeutics, Inc. | 58.34M |
| Anixa Biosciences, Inc. | -7.376M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -97.00M |
| Cash from Investing (Quarterly) | -104.08M |
| Cash from Financing (Quarterly) | 14.98M |
| Free Cash Flow Per Share (Quarterly) | -0.6759 |
| Free Cash Flow to Equity (Quarterly) | -124.25M |
| Free Cash Flow to Firm (Quarterly) | -126.61M |
| Free Cash Flow Yield | -13.28% |